Background: Post-traumatic stress disorder sharply increases the risk of depression and suicide. Individuals living with post-traumatic stress disorder frequently use cannabis to treat associated symptoms. We sought to investigate whether cannabis use modifies the association between post-traumatic stress disorder and experiencing a major depressive episode or suicidal ideation. Methods: We used data from the 2012 Canadian Community Health Survey-Mental Health, a nationally representative cross-sectional survey of noninstitutionalized Canadians aged ⩾15 years. The relationship between post-traumatic stress disorder and each outcome was modelled using logistic regression with an interaction term for cannabis and post-traumatic stress disorder, controlling for demographic characteristics, mental health, and substance use comorbidities. The ratio of odds ratios and relative excess risk due to interaction was calculated to measure interaction on the multiplicative and additive scales, respectively. Results: Among 24,089 eligible respondents, 420 (1.7%) reported a current clinical diagnosis of post-traumatic stress disorder. In total, 106 (28.2%) people with post-traumatic stress disorder reported past-year cannabis use, compared to 11.2% of those without post-traumatic stress disorder (p < 0.001). In multivariable analyses, post-traumatic stress disorder was significantly associated with recent major depressive episode (adjusted odds ratio = 7.18, 95% confidence interval: 4.32-11.91) and suicidal ideation (adjusted odds ratio = 4.76, 95% confidence interval: 2.39-9.47) among cannabis non-users. post-traumatic stress disorder was not associated with either outcome among cannabis-using respondents (both p > 0.05).
Introduction
Canada is estimated to have one of the highest prevalence estimates of lifetime post-traumatic stress disorder (PTSD) worldwide, affecting some 9.2% of the population (Duckers et al., 2016) . PTSD is a psychiatric diagnosis associated with surviving exposure to a traumatic life event (Shalev et al., 2017) , and involves symptoms of hyper-arousal and flashbacks, as well as impaired memory, concentration, and sleep (Bremner, 2006) . These symptoms are thought to manifest through stress-induced changes to the brain, resulting in disruptions to the body's stress response (Bremner, 2006) . It has been well established that PTSD, especially when coupled with comorbid depression, greatly increases the risk of suicidality (i.e. suicidal ideation (SI), plans, and attempts (Ramsawh et al., 2014) ) and completed suicide (Gradus et al., 2010) . Treating PTSD is challenging, particularly due to a substantial heterogeneity in treatment responses between patients (Shalev et al., 2017) .
Cannabis use and cannabis use disorder (CUD) are common among trauma survivors (Kevorkian et al., 2015) . Previous research among individuals with PTSD suggests that cannabis use is associated with increased PTSD symptom severity, poorer mental health (including depression and suicidality), and highrisk substance use (Gentes et al., 2016) . Individuals with severe or treatment-resistant PTSD symptomologies may use cannabis extra-medically or therapeutically as a primary or adjunctive therapy (Greer et al., 2014; Ruglass et al., 2017) . However, it has been posited that this type of coping-oriented motive may reflect an unhealthy pattern of using cannabis to avoid confronting painful trauma-related memories and experiences (i.e. "avoidance coping"), which could exacerbate PTSD symptoms in the long term (Bonn-Miller et al., 2007) . Much of the existing evidence in support of cannabis as a PTSD treatment is anecdotal and posits a range of therapeutic benefits including improving sleep, maintaining cognitive control, reducing symptoms of hyper-arousal, preventing intrusive thoughts, and managing emotional distress (Passie et al., 2012; Steenkamp et al., 2017) Discoveries involving the body's natural endogenous cannabinoid (eCB) system (see Discussion) and its role in regulating a range of PTSD-compromised neurobiological processes (e.g. fear, memory, stress, and sleep (Passie et al., 2012) ), have sparked interest in eCB modulators (i.e. natural and synthetic cannabinoids) as promising PTSD treatment agents (Shalev et al., 2017) . In the wake of these developments, the therapeutic use of cannabis for PTSD has gained a level of legitimacy across North America. For example, cannabis is an approved medication for PTSD in some states in the United States (US) (Steenkamp et al., 2017) , and Canadian physicians can authorize access to medical cannabis for the treatment of PTSD under the Access to Cannabis for Medical Purposes Regulations. In recent years, the number of Canadians, including veterans, incorporating cannabis into their PTSD treatment plan has grown dramatically (Veterans Affairs Canada, 2019). This increase in medical cannabis use for PTSD has overlapped with growing public awareness of the heightened risk of suicide among trauma-exposed populations (D'Aliesio, 2017) . However, the current state of scientific evidence is insufficient to conclude whether cannabis is beneficial or harmful to patients with PTSD (O'Neil et al., 2017) .
As Canada moves into the era of legalized cannabis, there are increasing scientific calls to explore the range of possible clinical applications involving cannabinoids, including the treatment of PTSD (Serrano, 2018) . Canada's first clinical trial to study the safety and efficacy of cannabis in managing treatmentresistant (i.e. approved medication or empirically supported psychotherapy) PTSD is underway (clinicaltrials.gov, 2015) and there are several ongoing clinical trials of cannabis for PTSD in the US (O'Neil et al., 2017) . In the interim, there is a valuable opportunity for epidemiological research to examine the complex relationships between PTSD, cannabis use, and mental health outcomes including suicidality.
This study draws on epidemiological data from a representative sample of Canadians to explore whether cannabis use modifies the relationship between PTSD and severe depressive and suicidal states. If cannabis offers a therapeutic benefit for PTSD, we would expect the relationship between PTSD and these markers of severe mental distress to be dependent on cannabis such that the association would be amplified in its absence and attenuated in its presence.
Methods

Study design
Data were obtained from Statistics Canada's 2012 Canadian Community Health Survey -Mental Health (CCHS-MH). Detailed sampling and interviewing methods for this cross-sectional study are available from Statistics Canada (Statistics Canada, 2013) . Briefly, the survey covers Canadians aged 15 or over living the 10 provinces and excludes approximately 3% of this target population who are: full-time members of the Canadian Armed Forces; individuals living on reserves or other First Nations, Inuit, or Métis settlements; and individuals held in correctional facilities. Multi-stage cluster sampling is used to obtain a geographically representative sample of the target population. In total, 25,113 participants completed the computer-assisted interview over the phone or in person, generating a combined household and person-level response rate of 68.9% (Statistics Canada, 2013) . Ethics approval for this study was covered by the University of British Columbia's publicly available data clause (Policy 89, Item 7.10.3) governing the use of public release data (2012). All data were kept private and confidential as part of the Statistics Act.
Measures
All respondents who provided valid responses to questions corresponding to variables of interest in the present study were eligible for analysis. The two outcomes of interest were: (a) past-year major depressive episode (MDE), defined as meeting the criteria for MDE, as assessed through a modified version of the World Health Organization Composite International Diagnostic Interview (WHO-CIDI), and (b) past-year SI, defined as answering "yes" to the question "In the past 12 months, did you seriously think about committing suicide or taking your own life?" Both outcomes were binary (yes vs. no). The exposure of interest was self-reported current PTSD diagnosis, defined as a medical diagnosis of PTSD that is expected to last, or has already lasted, 6 months or longer (yes vs. no). Cannabis use was defined as having used cannabis more than once in the previous year (yes vs. no). The question did not differentiate between medical and nonmedical use.
Additional socio-demographic variables considered in the analysis due to their known or a-priori hypothesized relationship with PTSD and MDE/SI were: sex (male vs. female); age (15-24 years, 25-44 years, 45-64 years vs. ⩾ 65 years); marital status (partner vs. single); visible minority (yes vs. no); education (< high school, high school vs. post-secondary); and annual household income (<$60,000 vs. ⩾ $60,000). The following past-year substance use and mental health comorbidities were also considered in the analyses: non-cannabis illicit drug use (yes vs. no); alcohol use disorder; and non-cannabis substance use disorder (yes vs. no). Both substance use disorder variables were defined as meeting criteria for abuse or dependence through a modified version of the WHO-CIDI. We also included measures of selfreported diagnoses of depression (yes vs. no); other mood disorder (yes vs. no); and anxiety disorder (including generalized anxiety disorder, panic disorder, and obsessive compulsive disorder; yes vs. no). Similar to the variable for PTSD, these mental health measures are clinical diagnoses of conditions that have lasted or are expected to last 6 months or longer.
Statistical analysis
Sample characteristics were examined using standard descriptive statistics. We used Pearson's Chi-square test to analyze bivariable associations between each independent variable and outcome.
We regressed MDE and SI on PTSD, separately, to calculate the unadjusted odds ratio (OR) for the association between PTSD and MDE/SI. Then, to explore whether this association was modified by cannabis use, we added cannabis and a cannabis-PTSD interaction term to each model. Wald tests were used to check the significance of the multiplicative interaction. Next, we conducted multivariable analyses to estimate the adjusted OR (AOR) for each outcome across strata of cannabis use. We followed an a-priori model building strategy in which all listed variables (except depression for the MDE model) were included as hypothesized confounders in the association between PTSD and MDE/ SI. AORs within each stratum of PTSD and cannabis use were also calculated by replacing the PTSD, cannabis, and interaction terms in each multivariable model with a four-category combined PTSD/cannabis variable (i.e. PTSD-/Cannabis-; PTSD+/ Cannabis-; PTSD-/Cannabis+; PTSD+/Cannabis+). The category hypothesized to have the lowest probability of SI and MDE (i.e. PTSD-/Cannabis-) provided the reference.
As per Knol and VanderWeele's effect modification reporting guidelines (2012), statistical interaction on the additive scale was tested by calculating the relative excess risk due to interaction (RERI) and its 95% confidence interval (CI) using the Delta method described by Hosmer and Lemeshow (1992) . The RERI can be estimated by approximating risk ratios from ORs in cases where the outcome is rare. A RERI of 0 means no interaction; a RERI bigger or smaller than 0 means positive or negative interaction on the additive scale, respectively (Knol et al., 2011) . Measuring interaction on the additive scale is generally considered more relevant in assessing the public health impact, as it indicates which exposure group would benefit the most from intervening on the effect modifier, or vice-versa (VanderWeele and Knol, 2014) . The ratio of odds ratios within the strata of cannabis use status is also reported as the measure of multiplicative interaction for each outcome. A ratio of 1 means no interaction, whereas a ratio bigger or smaller than 1 indicates positive or negative interaction on the multiplicative scale, respectively.
A sub-analysis was conducted among respondents with PTSD to estimate the adjusted odds of SI and MDE according to cannabis use intensity. We built two multivariable models (one for each outcome) with a three-level past-year cannabis intensity variable (low-risk, high-risk, vs. ⩽ one-time use) as the main exposure. "High-risk" use was defined as meeting the criteria for past-year CUD, as assessed through a modified version of the WHO-CIDI. "Low-risk" use was defined as not meeting the criteria for CUD either through the WHO-CIDI assessment or through not meeting the CCHS-MH/WHO-CIDI screening threshold (lifetime cannabis use ⩾ 50 times). This threshold was based on an expert review of 2011 CCHS-MH pilot data analyses.
All analyses were conducted in Stata version 14.2 (StataCorp LLC, College Station, TX) using standard univariable, bivariable, and multivariable procedures with 'svy' commands and probability weights to account for complex survey sampling methods. All p values are two sided.
Results
Of the 25,113 Canadians who were interviewed for the 2012 CCHS-MH, 24,089 (95.9%) provided complete data for this study and were included in the current analysis. The prevalence of current PTSD diagnosis was 1.7% (n = 420), and cannabis use more than once in the previous year was reported by 11.4% (n = 2767) of the overall sample; however, individuals living with PTSD had a significantly higher prevalence of past-year cannabis use relative to the rest of the sample (28.2% vs. 11.2%, p < 0.001). In total, 1261 (4.7%) respondents met the criteria for experiencing a past-year MDE and 875 (3.3%) reported past-year SI. Across strata of PTSD and cannabis use, the prevalence of each outcome was lowest among individuals who did not use cannabis and did not have PTSD. Table 1 summarizes sample characteristics overall, stratified by each outcome, and presents bivariable associations. PTSD was strongly and positively associated with MDE and SI. Cannabis use in the previous year was also significantly and positively associated with each outcome. The unadjusted interaction models generated significant interaction terms (MDE: p = 0.003; SI: p = 0.021). The cannabis-stratified ORs were split above and below the unadjusted pooled ORs. Among the sample that did not use cannabis, having PTSD was associated with 21.06 (95% CI: 13.41-33.07) times the odds of MDE and 19.91 (95% CI: 11.76-33.72) times the odds of SI, relative to individuals with PTSD (both p < 0.001). In contrast, among the sample that reported cannabis use, PTSD was associated with 6.33 (95% CI: 3.29-12.17) times the odds of MDE and 7.1 (95% CI: 3.5-14.2) times the odds of SI, relative to individuals without PTSD (both p < 0.001). These unadjusted results can be extrapolated from data provided in Tables 2 and 3. Tables 2 and 3 present the results of the multivariable regression within combined stratum of PTSD and cannabis use (left) and within strata of cannabis use (right) for MDE (Table 2) and SI (Table 3) . After controlling for socio-demographic factors, cooccurring substance use patterns, and comorbid mental health problems, PTSD remained positively and significantly associated with MDE (AOR = 7.18; 95% CI = 4.32-11.91) and SI (AOR = 4.76; 95% CI = 2.39-9.47) among cannabis non-users (both p < 0.001). However, there was no longer a significant association between PTSD and MDE (AOR = 1.77; 95% CI = 0.79-3.97) or PTSD and SI (AOR = 1.66; 95% CI = 0.77-3.56) among respondents who reported cannabis use more than once in the previous year (both p > 0.05).
On the multiplicative scale, there was a significant negative interaction between PTSD and cannabis use, with both ratio of ORs < 1 (p < 0.05). Tests for additive interaction for MDE provided strong indication that the estimated effect of PTSD on MDE among cannabis users was less than the effect of PTSD on MDE for non-users (RERI = -4.93, 95% CI: -8.49--1.37; p = 0.007). The RERI for the PTSD and cannabis on SI was negative, but fell short of statistical significance (p = 0.125).
In sub-analyses among 420 respondents with PTSD (Table 4) , cannabis use in the previous year was not significantly associated with MDE or SI (both p > 0.05). Separation of cannabis use into "low risk" (n = 86; 23.6%) and "high risk" (n = 20; 4.5%) revealed a negative association between low-risk use and SI shy of significance (p = 0.068) and a significant negative association between low-risk cannabis use and MDE (p = 0.038). High-risk cannabis use was not associated with either outcome (both p > 0.05).
Discussion
This is the first study, to our knowledge, to document the relationships between PTSD, cannabis use, and severe mental health outcomes in a representative population sample. Over one-quarter of Canadians with PTSD reported past-year cannabis use, which is remarkably high compared to the prevalence of recent use in the general Canadian population (estimated at 11.4% in the present study), and the prevalence of recent use among US adults with lifetime PTSD (14.0%) (Cougle et al., 2011) . Through the novel conceptual and methodological treatment of cannabis as an effect measure modifier, this study provides evidence that cannabis use may reduce the effect of PTSD on MDE and SI. Relative to Canadians without either exposure, the odds of MDE and SI were elevated among individuals with PTSD and individuals who use cannabis. Yet, exposure to both these risk factors produced a smaller effect on MDE (multiplicative and additive scales) and SI (multiplicative scale) than expected based on their individual effect estimates. A more straightforward way of interpreting these findings is within strata of cannabis use: whereas PTSD was strongly linked to MDE and SI among the cannabis non-using population, PTSD was not associated with either outcome among Canadians who used cannabis. Furthermore, sub-analyses involving respondents with PTSD suggested that lower-risk cannabis users are even less likely than non-users to experience MDE or SI (although the estimate for SI was shy of reaching significance). These benefits were not observed for individuals engaging in high-risk cannabis use (see discussion below). In general, PTSD can be classified according to three symptom groups: re-experiencing (e.g. flashbacks, reliving the traumatic experience), hyper-arousal (e.g. irritability, difficulty concentrating, lowered tolerance to stressful stimuli), and avoidance/numbing behaviors (e.g. attempting to avoid aversive situations or emotional thoughts/feelings) (Pai et al., 2017) . Cross-sectional studies have observed significant correlations between cannabis use and higher PTSD symptom severity (Bordieri et al., 2014; Earleywine and Bolles, 2014; Gentes et al., 2016) . Research by Bonn-Miller et al. (2007) suggests this association is explained by increased motivation to use cannabis for coping purposes among those with higher symptom severity. However, whether coping-motivated cannabis strategies effectively manage symptoms or simply facilitate avoidance/numbing-potentially contributing to intensified symptoms (Pineles Measure of effect modification on additive scale: RERI (95% CI) = -4.93 (-8.49 , -1.37); p = 0.007. Measure of effect modification on the multiplicative scale: ratio of ORs (95% CI) = 0.25 (0.10, 0.64); p = 0.004. OR is adjusted for age, sex, marital status, visible minority, education, household income, other illicit drug use, mood disorder excl. depression, anxiety disorder, alcohol use disorder, and other substance use disorder. n is a raw cell count; % is weighted. Unadjusted OR point estimates can be calculated from weighted cell counts (multiply the weighted proportions with and without the outcome in each cell by the total n in that cell). CI: confidence interval; MDE: major depressive episode; OR: odds ratio; PTSD: post-traumatic stress disorder; RERI: relative excess risk due to interaction. 2.37 (1.13-4.97); p = 0.023 1.66 (0.77-3.56); p = 0.194
Measure of effect modification on additive scale: RERI (95% CI) = -2.82 (-6.42, 0.78); p = 0.125. Measure of effect modification on the multiplicative scale: ratio of ORs (95% CI) = 0.35 (0.13-0.94); p = 0.038. OR is adjusted for age, sex, marital status, visible minority, education, household income, other illicit drug use, depression, other mood disorder, anxiety disorder, alcohol use disorder, and other substance use disorder. n is a raw cell count; % is weighted. Unadjusted OR point estimates can be calculated from weighted cell counts (multiply the weighted proportions with and without the outcome in each cell by the total n in that cell). CI: confidence interval; SI: suicidal ideation; PTSD: post-traumatic stress disorder; RERI: relative excess risk due to interaction. et al., 2011)-is not entirely clear. In a recent longitudinal study among PTSD patients initiating non-pharmacological treatment, patients who used cannabis weekly reported higher symptom severity at treatment initiation, but experienced a 75% reduction in all assessed symptoms, including avoidance, over 12 weeks (Ruglass et al., 2017) , providing some evidence for the symptommanagement hypothesis. Similarly, a >75% reduction in symptom severity was recorded in a retrospective analysis of 80 PTSD patients in New Mexico's medical cannabis program (Greer et al., 2014) . In contrast, Wilkinson et al. (2015) conducted a retrospective chart review of over 2000 veterans referred for PTSD treatment and noted that patients who started using cannabis over the 4-month treatment period experienced an increase in treatment severity, whereas patients who stopped using cannabis experienced improvements. The relationship between problematic cannabis use (i.e. CUD) and PTSD symptom severity has been the focus of several observational studies Bonn-Miller et al., 2013; Bordieri et al., 2014) . One hypothesis is that CUD is implicated in a feedback loop with PTSD symptomology whereby cannabis is used for symptom management, but symptoms intensify during cessation periods via withdrawal, leading to a relapse of cannabis use for symptom management . There is also some evidence that increased PTSD symptom severity is predictive of CUD only when cannabis is used as a strategy of avoidance (Bordieri et al., 2014) . Through a sub-analysis of participants with PTSD, our study considered how PTSD could be distinctly linked with mental health outcomes according to higher-and lower-risk use patterns. Although larger observational and experimental studies are warranted, the results of this sub-analysis suggest cannabis may be used as an effective form of PTSD symptom management among lower-risk cannabis users (>80% of all cannabis users in this sub-sample), but not among those exhibiting higher-risk usage patterns. One possible explanation is that high-risk use is a marker of unhealthy avoidance coping in this sub-sample. It is also possible that problematic patterns of cannabis use may trigger certain negative social and psychological effects common to PTSD (e.g. paranoia (Freeman et al., 2013) ), which could contribute to intensified PTSD symptoms and degradation of longer-term mental health (Tsai et al., 2014) . Individuals using cannabis to treat traumaassociated symptoms should therefore be carefully monitored for the development of CUD.
A growing pre-clinical research base has identified a potential modulating role of the eCB system in the manifestation of PTSD. The eCB system is comprised of type-1 cannabinoid receptors (CB-1), predominantly in the central nervous system; CB-2, predominantly in the peripheral nervous system; and eCB ligands including N-arachidonoyl ethanolamine (anandamide) and 2-arachidonoyl glycerol that bind to these receptors to regulate neurotransmitter release (Hillard, 2015) . CB-1 is abundant in stress-related regions of the brain including the amygdala, hippocampus, and prefrontal cortex (Trezza and Campolongo, 2013; Zer-Aviv et al., 2016) . These regions are involved in emotional and memory processes that tend to be disrupted in PTSD, such as the detection and regulation of emotions, and storage of fear memories (Passie et al., 2012; Trezza and Campolongo 2013; Zer-Aviv et al., 2016) . Human brain imaging studies have shown that patients with PTSD exhibit higher levels of CB-1 and lower levels of the eCB anandamide in these regions compared to individuals without PTSD (Neumeister et al., 2013) , providing a possible neuropharmacological rationale for cannabinoid supplementation in the treatment of PTSD. In animal models, exposure to cannabinoids following exposure to trauma prevents the development of certain effects from trauma, including impaired fear extinction and stress-induced anxiety (Zer-Aviv et al., 2016) . Rigorous experimental research is needed to understand if humans exhibit a similar response.
Sleep is a commonly reported therapeutic motive for medical cannabis use (Reinarman et al., 2011) , including among PTSD patients (Bonn-Miller et al., 2014) . A small number of pilot clinical trials have been conducted to determine the efficacy, safety, and tolerance of cannabinoids for relief of PTSD-associated insomnia and nightmares. Two studies noted cessation or reduced severity of nightmares after treatment with nabilone (a synthetic analogue of tetrahydrocannabinol (THC)) (Fraser, 2009; Jetly et al., 2015) . Roitman et al. (2014) observed significant improvements in PTSD symptoms and sleep quality with oral THC. Cannabinoids were relatively safe and well tolerated, with a small number of mild side effects (e.g. dizziness, short-term memory impairments) (Fraser, 2009 ). However, the plausibility of sleep management as a pathway underlying the current findings is challenged by other Canadian research demonstrating that the relative impact of insomnia on SI is reduced in the presence of comorbid mental health problems including PTSD (Richardson et al., 2017) . Future experimental studies will need to address the role of sleep in the relationship between cannabinoid therapy and PTSD outcomes.
The major strength of this study is its external validity through the use of a representative sample of Canadians from the 10 provinces. However, a number of limitations are also worth considering. First, the cross-sectional study design prevents the ability to confirm the sequence of exposures for PTSD, cannabis use, and MDE/SI, thus preventing causal interpretations. In particular, cannabis use in this study was measured over the previous year, whereas PTSD referred to a current diagnosis (i.e. has lasted or is expected to last 6 months or longer). It is possible that some PTSD patients engaged in cannabis use ahead of their diagnosis but not after. Second, as this was a secondary analysis of a Statistics Canada survey, we had no role in questionnaire development and were limited to the variables available in the dataset. As such, it was not possible to ascertain information on a number of details. For example, the study did not provide information on licensed medical cannabis patient status, or whether cannabis use was considered medicinal or recreational by the participant. The data collection period preceded the creation of a commercially licensed industry for medical cannabis, meaning any licensed medical use at the time of study would have occurred through the more restrictive 2001-2013 "Marihuana [sic]" for Medical Access Regulations system. We also did not have access to information on dose, potency, strain, or mode of cannabis administration. Although this is a common limitation of observational research involving cannabis, awareness is growing amongst clinical and public health researchers that these details are critical to understanding the health and social risks and benefits of cannabis use (Solowij et al., 2016) , particularly against the evolving cannabis policy backdrop. Because the study was limited to variables available through the CCHS-MH, it may be susceptible to residual confounding. Third, although only 3% of the target population was excluded from the survey sample pool, certain excluded groups are likely to have a high prevalence of PTSD (e.g. full-time members of the Canadian armed forces, indigenous populations living on settlements or reserves). The relevance and generalizability of this work would be optimized through future studies using a similar methodological approach with data from these sub-populations in the era of Canada's commercial medical cannabis system. Fourth, many outcomes were self-reported and subject to recall inaccuracies and reporting according to perceived social norms. This could bias the study outcomes if there were systematic differences in the accuracy of reporting according to exposure status. However, this is unlikely to be the case in the present study, because these responses were extracted from a larger survey assessing a broad set of healthrelated factors among Canadians, and participants were not aware of specific research questions to be explored with this data. Finally, given a low prevalence of PTSD in the study population, the trends revealed through the current sub-analysis will need to be assessed in future studies with larger representative samples of individuals with PTSD.
In sum, this study provides compelling preliminary evidence from a general population sample that cannabis use modifies the association between PTSD and depression and suicidality, such that the associations appear to be strengthened in the absence of cannabis use and tempered in the presence of lower-risk cannabis use. However, a number of limiting factors prevent the ability to determine a causal connection. Despite the overall findings of this study suggesting a possible therapeutic benefit of cannabis use in the treatment of PTSD, cannabis use is not without risks, including the development of CUD. High-quality randomized controlled trials that can measure the possible effect of therapeutic cannabis use on PTSD-specific symptoms as well as these broader mental health outcomes over time are urgently needed to elucidate whether the current finding is in fact indicative of a biological interaction.
